• AbbVie pays a quarterly dividend of $1.73 per share, or $6.92 annually, for a 2.77% forward yield.
• Second-quarter revenue rose 10.2% to $16.99 billion as Skyrizi and Rinvoq combined for more than $8 billion in sales.
• The proposed $10.9 billion Apogee Therapeutics acquisition could expand AbbVie’s pipeline but is expected to reduce 2026 adjusted EPS by $0.14.

ABBV dividends remain supported by earnings growth

AbbVie pays a quarterly dividend of $1.73 per share, equal to $6.92 annually. At a share price near $249.46, ABBV dividends offer a 2.77% forward dividend yield.

The payout was unchanged from the prior quarter but increased from $1.64 a year earlier. AbbVie has more than 50 consecutive years of annual dividend increases, including its Abbott heritage, supporting its appeal to investors seeking rising income.

However, the current 2.77% AbbVie dividend yield is below the company’s roughly 3.74% five-year average. That indicates the share price reflects considerable optimism about its growth outlook.

Q2 growth strengthens the post-Humira outlook

AbbVie’s second-quarter performance was strong, with revenue rising 10.2% to $16.99 billion and adjusted EPS increasing 22.9% to $3.65.

Immunology remains central to the investment case. Skyrizi generated $5.51 billion in quarterly sales, up 24.4%, while Rinvoq delivered $2.53 billion, up 24.5%.

Combined sales above $8 billion dwarfed Humira’s $756 million in quarterly revenue, despite Humira declining nearly 36% amid biosimilar competition. Durable growth from Skyrizi and Rinvoq can support research spending and future ABBV dividend increases.

Using management’s adjusted EPS guidance of $13.87 to $14.07, the $6.92 annual dividend represents roughly half of expected adjusted earnings. That is a reasonable earnings-based coverage level.

Apogee deal brings opportunity and pressure

The proposed $10.9 billion Apogee Therapeutics acquisition is expected to reduce 2026 adjusted EPS by $0.14. The transaction could add long-acting immunology treatments and extend AbbVie’s growth runway.

It also introduces financing, integration and clinical-development risks. Income investors should monitor leverage, deleveraging progress and whether acquired pipeline assets justify the delayed earnings benefit.

ABBV valuation limits the yield appeal

ABBV trades about 7% below its 52-week high of $267.47. A $276.41 consensus price target and a $325 bullish 2027 scenario imply roughly 11% and 30% upside, respectively, from the current price.

AbbVie remains a dividend-growth stock rather than a high-yield bargain. Long-term income investors could consider gradual purchases or dividend reinvestment while avoiding an oversized position before the next earnings report on October 29.